Back to top

rsi: Archive

Zacks Equity Research

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

Surrozen (SRZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

SRZNPositive Net Change

Zacks Equity Research

After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)

Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

INGNPositive Net Change

Zacks Equity Research

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

ALLOPositive Net Change

Zacks Equity Research

Down -9.16% in 4 Weeks, Here's Why Exelon (EXC) Looks Ripe for a Turnaround

Exelon (EXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

EXCNegative Net Change

Zacks Equity Research

After Plunging -5.25% in 4 Weeks, Here's Why the Trend Might Reverse for New Jersey Resources (NJR)

The heavy selling pressure might have exhausted for New Jersey Resources (NJR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

NJRNegative Net Change

Zacks Equity Research

Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

TARSNegative Net Change

Zacks Equity Research

Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround

Sera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SERANegative Net Change

Zacks Equity Research

Down -57.05% in 4 Weeks, Here's Why You Should You Buy the Dip in AZUL (AZUL)

The heavy selling pressure might have exhausted for AZUL (AZUL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AZULNegative Net Change

Zacks Equity Research

Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround

Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

MYGNPositive Net Change

Zacks Equity Research

After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

PHATNegative Net Change

Zacks Equity Research

Down -20.26% in 4 Weeks, Here's Why LifeStance Health (LFST) Looks Ripe for a Turnaround

LifeStance Health (LFST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

LFSTNegative Net Change

Zacks Equity Research

Here's Why HealthStream (HSTM) is Poised for a Turnaround After Losing -13.2% in 4 Weeks

HealthStream (HSTM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

HSTMNegative Net Change

Zacks Equity Research

Prairie Operating Co. (PROP) Loses -36.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Prairie Operating Co. (PROP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PROPNegative Net Change

Zacks Equity Research

After Plunging -26.98% in 4 Weeks, Here's Why the Trend Might Reverse for Iridium (IRDM)

Iridium (IRDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

IRDMPositive Net Change

Zacks Equity Research

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

ESPRPositive Net Change

Zacks Equity Research

Down -25.21% in 4 Weeks, Here's Why AerSale (ASLE) Looks Ripe for a Turnaround

AerSale (ASLE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

ASLENegative Net Change

Zacks Equity Research

Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround

OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

OPKNo Net Change

Zacks Equity Research

After Plunging -18.95% in 4 Weeks, Here's Why the Trend Might Reverse for AGNC Investment (AGNC)

AGNC Investment (AGNC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

AGNCPositive Net Change

Zacks Equity Research

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

Seres Therapeutics (MCRB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

MCRBPositive Net Change

Zacks Equity Research

Here's Why Phibro (PAHC) is Poised for a Turnaround After Losing -22.25% in 4 Weeks

Phibro (PAHC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PAHCNegative Net Change

Zacks Equity Research

Down -21.15% in 4 Weeks, Here's Why You Should You Buy the Dip in Criteo (CRTO)

Criteo (CRTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

CRTONegative Net Change

Zacks Equity Research

SmartRent, Inc. (SMRT) Loses -37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SmartRent, Inc. (SMRT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SMRTNegative Net Change

Zacks Equity Research

Down -20.93% in 4 Weeks, Here's Why Sprout Social (SPT) Looks Ripe for a Turnaround

Sprout Social (SPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

SPTNegative Net Change

Zacks Equity Research

After Plunging -24.73% in 4 Weeks, Here's Why the Trend Might Reverse for Orchid Island (ORC)

Orchid Island (ORC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

ORCNegative Net Change

Zacks Equity Research

After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)

The heavy selling pressure might have exhausted for IMab (IMAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

IMABPositive Net Change